Worldwide Network for Blood and Marrow Transplantation (WBMT) Recommendations Regarding Essential Medications Required To Establish An Early Stage Hematopoietic Cell Transplantation Program

Fakih, Riad El; Greinix, Hildegard; Koh, Mickey; Shaw, Bronwen E.; Mohty, Mohamad; Nahedh, Mohammad Al; Saber, Wael; Kharfan‐Dabaja, Mohamed A.; Perales, Miguel Angel; Savani, Bipin N.; Majhail, Navneet S.; Passweg, Jakob; Sureda, Anna; Ahmed, Syed Osman; Gluckman, Éliane; Riches, Marcie L.; El‐Jawahri, Areej; Rondelli, Damiano; Srivastava, Alok; Faulkner, Lawrence; Atsuta, Yoshiko; Ballen, Karen K.; Rasheed, Walid; Okamoto, Shinichiro; Seber, Adriana; Chao, Nelson J.; Kodera, Yoshihisa; Szer, Jeff; Hashmi, Shahrukh K.; Horowitz, Mary M.; Weisdorf, Daniel J.; Niederwieser, Dietger; Aljurf, Mahmoud

doi:10.1016/j.jtct.2020.12.015

Cited by 7 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Advance careful planning is crucial when designing the HSC transplant program to meet the expected challenges [66]. Therefore, when creating the national HSCT program, we should consider the role of national traditions and opportunities in such interdisciplinary areas of the process providing as cryobiology and cryomedicine.…”

Section: Discussionmentioning

confidence: 99%

Multidisciplinary Development Issues of Hematopoietic Stem Cell Transplantation Program in Ukraine: Role of Auxiliary Cryopreservation Technologies

Kalynychenko

2021

J. Hematol. Res.

View full text Add to dashboard Cite

Hematopoietic stem cell transplantation (HSCT) is a life-saving medical technology for many serious diseases. Active international exchange of transplant material is ensured through productive cooperation of world international donation, transplantation, cell therapy organizations, along with their associations. Analysis of the experience of many countries has allowed the development of key recommendations from the Worldwide Network for Blood and Marrow Transplantation for establishing HSCT programs. According to them, to make the most effective use of the capabilities of this medical technology, the creation of new transplant programs requires both sufficient investment and the presence of specialized professional teams for multidisciplinary support of the entire process. This article discusses prospects for the development of the national transplant program in Ukraine. In particular, the role of Ukrainian national scientific and practical traditions detailed in the creation of cellular processing technologies and cryopreservation as part of the team support providing components of transplantation medical technology. It is looked forward that the development of the HCST program in Ukraine will take place through continuous improvement in order to meet the criteria of the highest quality and safety. Its serious basis is the solid scientific traditions, historical and modern experience of many directions that provide the field.

show abstract

Section: Discussionmentioning

confidence: 99%

Multidisciplinary Development Issues of Hematopoietic Stem Cell Transplantation Program in Ukraine: Role of Auxiliary Cryopreservation Technologies

Kalynychenko

2021

J. Hematol. Res.

View full text Add to dashboard Cite

show abstract

“…According to a retrospective evaluation of worldwide HSCT activity trends conducted by the Worldwide Network for Blood and Marrow Transplantation (WBMT), more than 1,298,897 HSCT procedures were carried out between 1957 and 2016. WBMT is an association of societies involved in cellular therapies (stem cell transplantation, stem cell donation, and cellular therapy) with the mission of promoting excellence in HSCT ( 27 , 28 ). In 2016 alone, 89,070 HSCT procedures were conducted across 1,662 centers across the globe ( 29 ).…”

Section: Hematopoietic Stem Cell Transplantationmentioning

confidence: 99%

The Impact of Human Microbiotas in Hematopoietic Stem Cell and Organ Transplantation

Sen

Thummer

2022

Front. Immunol.

View full text Add to dashboard Cite

The human microbiota heavily influences most vital aspects of human physiology including organ transplantation outcomes and transplant rejection risk. A variety of organ transplantation scenarios such as lung and heart transplantation as well as hematopoietic stem cell transplantation is heavily influenced by the human microbiotas. The human microbiota refers to a rich, diverse, and complex ecosystem of bacteria, fungi, archaea, helminths, protozoans, parasites, and viruses. Research accumulating over the past decade has established the existence of complex cross-species, cross-kingdom interactions between the residents of the various human microbiotas and the human body. Since the gut microbiota is the densest, most popular, and most studied human microbiota, the impact of other human microbiotas such as the oral, lung, urinary, and genital microbiotas is often overshadowed. However, these microbiotas also provide critical and unique insights pertaining to transplantation success, rejection risk, and overall host health, across multiple different transplantation scenarios. Organ transplantation as well as the pre-, peri-, and post-transplant pharmacological regimens patients undergo is known to adversely impact the microbiotas, thereby increasing the risk of adverse patient outcomes. Over the past decade, holistic approaches to post-transplant patient care such as the administration of clinical and dietary interventions aiming at restoring deranged microbiota community structures have been gaining momentum. Examples of these include prebiotic and probiotic administration, fecal microbial transplantation, and bacteriophage-mediated multidrug-resistant bacterial decolonization. This review will discuss these perspectives and explore the role of different human microbiotas in the context of various transplantation scenarios.

show abstract

“…Several different specialty consultants, such as infectious disease, cardiology, nephrology, nutrition, psychiatry, and intensive care, are also needed per the international accreditation guidelines [ 6 ]. Furthermore, strong pharmaceutical support is pivotal for provisional drugs used specifically in allogeneic HPCT [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

Developing an Allogeneic Hematopoietic Progenitor Cell Transplant Service in a Resource-Limited Country: Challenges and Outcomes

Mahar,

Ahsan,

Ahmad

et al. 2023

Cureus

View full text Add to dashboard Cite

Introduction Allogeneic stem cell transplant has curative potential for many hematological disorders. Building an allogeneic hematopoietic progenitor cell transplant (HPCT) unit requires huge investment, infrastructure, equipment, medical supplies, and training of health care professionals. The key objective of this study is to share our experience of developing an allogeneic HPCT service at our tertiary care cancer hospital in a low-middle-income country. In addition, this study presents the outcomes of the first 30 allogeneic HPCTs done at our center. Methods This retrospective observational study included adult patients 18 years old or older with hematological malignancies who underwent allogeneic HPCT between July 2019 and April 2023 at Shaukat Khanum Memorial Cancer Hospital and Research Centre. Result Of the 30 patients, 24 underwent matched sibling donor (MSD) transplants in which a myeloablative-conditioning regimen (MAC) was used in 19, and a reduced conditioning regimen (RIC) was used in one. Of the six haploidentical-related donor transplants, four received MAC, and two received RIC. The median recipient age at HPCT was 23 and 21 years for MSD and Haplo-related donor transplants, respectively. The median follow-up duration was 12 months (Range: 10 days - 33 months). The overall survival rate at one year was 71.3% among all allogeneic stem cell transplant patients, whereas the disease-free survival rate at one year was 63.7%. In the acute lymphoblastic leukemia group, the disease-free survival rate at one year post allograft was 51.5%, while in the acute myeloid leukemia group, it was 78.7%. Conclusion This study demonstrates the successful development of an allogeneic bone marrow transplant unit at our hospital despite significant financial constraints. This has allowed us to provide a potentially curative and life-saving treatment to a substantial number of cancer patients. The bone marrow transplant outcomes of this study are comparable to those reported by international bone marrow transplant registries.

show abstract

Worldwide Network for Blood and Marrow Transplantation (WBMT) Recommendations Regarding Essential Medications Required To Establish An Early Stage Hematopoietic Cell Transplantation Program

Cited by 7 publications

References 14 publications

Multidisciplinary Development Issues of Hematopoietic Stem Cell Transplantation Program in Ukraine: Role of Auxiliary Cryopreservation Technologies

Multidisciplinary Development Issues of Hematopoietic Stem Cell Transplantation Program in Ukraine: Role of Auxiliary Cryopreservation Technologies

The Impact of Human Microbiotas in Hematopoietic Stem Cell and Organ Transplantation

Developing an Allogeneic Hematopoietic Progenitor Cell Transplant Service in a Resource-Limited Country: Challenges and Outcomes

Contact Info

Product

Resources

About